EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Patient-derived organoids (PDOs): a novel preclinical platform to overcome challenges in cancer immunotherapy

Dongmei Ni, Junjie Xing, Gengming Niu, Jingjing Qiu, Guiying Wei, Gang Chen, Qinghe Zhou, Xiaolan Yin

Frontiers in Cell and Developmental Biology · 18.02.2026 · 14

DOI: 10.3389/fcell.2026.1757516 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 18.02.2026. Verfasst von Dongmei Ni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Shanghai 411 Hospital, China RongTong Medical Healthcare Group Co., Ltd./411 Hospital, Shanghai University, Shanghai, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy has revolutionized oncology but faces significant challenges including low response rates and lack of effective preclinical models. This review elucidates how patient-derived organoids (PDOs) are emerging as a transformative platform to address these hurdles. We detail sophisticated immuno-PDO (iPDO) models, categorized into reconstituted systems (co-culturing PDOs with exogenous immune cells) and native systems (preserving endogenous tumor microenvironment via Air-Liquid Interface or Patient-Derived Organotypic Tumor Spheroids). A problem-solution framework demonstrates how iPDOs: (1) deconvolute the immunosuppressive TME; (2) function as “living biomarkers” for predicting clinical responses; (3) unravel resistance mechanisms via multi-omics; and (4) empower high-throughput screening for personalized combination therapies. Integration with bioengineering, multi-omics, and AI heralds a new era in precision immuno-oncology, holding immense promise for deciphering resistance and improving clinical outcomes.

Schlagwörter

Stichwörter der Autor:innen

biomarkercancer immunotherapyimmune checkpoint inhibitors (ICIs)patient-derived organoids (PDOs)tumor microenvironment (TME)

Autor:innen und Institutionen

  • Cancer Center, Shanghai 411 Hospital, China RongTong Medical Healthcare Group Co., Ltd./411 Hospital, Shanghai University, Shanghai, China.
  • Department of Colorectal Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
  • Shanghai OneTar Biomedicine, Shanghai, China.
  • Jiaxing Key Laboratory of Basic Research and Clinical Translation on Orthopedic Biomaterials, Department of Orthopaedics, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
  • Jiaxing Organoid Center, Jiaxing, China.

Zitieren

APA

Ni, D., Xing, J., Niu, G., Qiu, J., Wei, G., Chen, G., Zhou, Q., & Yin, X. (2026). Patient-derived organoids (PDOs): a novel preclinical platform to overcome challenges in cancer immunotherapy. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1757516

Vancouver

Ni D, Xing J, Niu G, Qiu J, Wei G, Chen G, et al. Patient-derived organoids (PDOs): a novel preclinical platform to overcome challenges in cancer immunotherapy. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1757516

BibTeX
@article{Ni2026,
  author = {Ni, Dongmei and Xing, Junjie and Niu, Gengming and Qiu, Jingjing and Wei, Guiying and Chen, Gang and Zhou, Qinghe and Yin, Xiaolan},
  title = {Patient-derived organoids (PDOs): a novel preclinical platform to overcome challenges in cancer immunotherapy},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2026},
  volume = {14},
  doi = {10.3389/fcell.2026.1757516}
}
Kostenlos starten →